# Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients

Study · id `cardio:ct-nct01422876` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01422876](<https://clinicaltrials.gov/study/NCT01422876>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01422876

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1405 participants.

## Technical summary

Registry record NCT01422876. Randomized; double masking; primary purpose treatment. Start 2011-08 (registry gives no type); primary completion 2013-09 (actual). Results posted on 2015-04-02.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1405 participants (enrolled count; ClinicalTrials.gov record NCT01422876, source copy `cardio:ctgov-nct01422876-2015-04-02`, retrieved 2026-10-26)
- Start date: 2011-08 (registry gives no type) (ClinicalTrials.gov record NCT01422876, source copy `cardio:ctgov-nct01422876-2015-04-02`, retrieved 2026-10-26)
- Primary completion: 2013-09 (actual) (ClinicalTrials.gov record NCT01422876, source copy `cardio:ctgov-nct01422876-2015-04-02`, retrieved 2026-10-26)
- Completion: 2013-09 (actual) (ClinicalTrials.gov record NCT01422876, source copy `cardio:ctgov-nct01422876-2015-04-02`, retrieved 2026-10-26)
- Results first posted: 2015-04-02 (ClinicalTrials.gov record NCT01422876, source copy `cardio:ctgov-nct01422876-2015-04-02`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Brazil; Bulgaria; Canada; Colombia; Denmark; Estonia; Hungary; Italy; Lebanon; Malaysia; Mexico; Peru; Philippines; Poland; Romania; Russia; Spain; Sweden; Taiwan (ClinicalTrials.gov record NCT01422876, source copy `cardio:ctgov-nct01422876-2015-04-02`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01422876-2015-04-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): high dose FDC
- Intervention (Drug): BI 10773 high dose
- Intervention (Drug): high dose FDC placebo
- Intervention (Drug): low dose FDC placebo
- Intervention (Drug): high dose FDC placebo
- Intervention (Drug): high dose FDC placebo
- Intervention (Drug): low dose FDC placebo
- Intervention (Drug): low dose FDC placebo
- Intervention (Drug): high dose BI 10773 placebo
- Intervention (Drug): low dose FDC
- Intervention (Drug): high dose FDC placebo
- Intervention (Drug): BI 10773 low dose
- Intervention (Drug): high dose BI 10773 placebo
- Intervention (Drug): high dose BI 10773 placebo
- Intervention (Drug): linagliptin
- Intervention (Drug): low dose FDC placebo
- Intervention (Drug): linagliptin placebo
- Intervention (Drug): BI 10773 low dose placebo
- Intervention (Drug): linagliptin placebo
- Intervention (Drug): low dose BI 10773 placebo
- Intervention (Drug): linagliptin placebo
- Intervention (Drug): high dose BI 10773 placebo
- Intervention (Drug): BI 10773 low dose placebo
- Intervention (Drug): low dose BI 10773 placebo
- Intervention (Drug): linagliptin placebo
- Lead sponsor: Boehringer Ingelheim
- Lead sponsor class: INDUSTRY
- Collaborator: Eli Lilly and Company
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Boehringer Ingelheim (`cardio:boehringer-ingelheim`)
- Registry lists this organization as a collaborator: Eli Lilly and Company (`cardio:eli-lilly`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin (`cardio:pubmed-25583754`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes (`cardio:pubmed-25633662`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Safety and Tolerability of Combinations of Empagliflozin and Linagliptin in Patients with Type 2 Diabetes: Pooled Data from Two Randomized Controlled Trials (`cardio:pubmed-29949041`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 167e2d188719d6353b5b778c02e038282dc9bdb33d6037f153690511e471bea6
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
